Karin A. Kook

High versus low dosing of oral colchicine for early acute gout flare: Twenty‐four–hour outcome of the first multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, dose‐comparison colchicine study

Robert Terkeltaub, Daniel E. Furst, Katherine Bennett et al. · Arthritis & Rheumatism · 2010 · 520 citations

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Serge Gauthier, Howard Feldman, Lon S. Schneider et al. · The Lancet · 2016 · 405 citations · Full text

Neurodegenerative Diseases, Alzheimer's Disease, Pharmacology +10

Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease

Claude M. Wischik, Roger T. Staff, Damon Wischik et al. · Journal of Alzheimer s Disease · 2015 · 251 citations · Full text

Neurodegenerative Diseases, Alzheimer's Disease, Biochemistry +15

Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitors

Robert Terkeltaub, Daniel E. Furst, Jennifer L. DiGiacinto et al. · Arthritis & Rheumatism · 2011 · 226 citations

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Gordon Wilcock, Serge Gauthier, Giovanni B. Frisoni et al. · Journal of Alzheimer s Disease · 2017 · 210 citations · Full text